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Early data are now appearing relating to the
measurement of biomarkers of acute kidney injury
during renal replacement therapy. These data go
some way in describing the clearance of these
molecules during renal support. Understanding the
potential clearance, or otherwise, of these proteins
may lead to directing our therapies in the future
particularly with regard to cessation of renal support.
We describe a recent study which has provided data
that may aid in addressing this issue.surgery and found that serial NGAL levels were poor pre-Acute kidney injury (AKI) remains a frequent complica-
tion of critical illness. The limitations of both the serum
creatinine and the urine output in alerting the clinician
to renal injury have catalyzed the growing body of re-
search examining candidate molecules which may pro-
vide an earlier signal highlighting the presence of renal
injury. The study by Schilder and colleagues [1] in the
previous issue of Critical Care examines one of the more
popular markers of AKI, namely neutrophil gelatinase-
associated lipocalin (NGAL), but rather than writing an-
other article on the accuracy of NGAL to diagnose AKI,
the authors focus on the effects of renal replacement
therapy (RRT) on NGAL levels.
NGAL is a member of the lipocalin family of proteins
that transport small hydrophobic ligands and has numer-
ous roles in inflammatory processes as well as cancer [2].
NGAL expression has been reported in many tissues where
it may provide protection against bacterial infection and* Correspondence: lui.forni@wsht.nhs.uk
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2014modulate oxidative stress. Moreover, it shows some prom-
ise as a potential biomarker for the early diagnosis of AKI
along with other potential candidates [3-5]. So given that
NGAL may herald AKI, why is this study of interest? One
could argue that employment of RRT already implies renal
injury and hence knowledge of its occurrence is somewhat
superfluous. There is evidence that, in addition to helping
to diagnose AKI earlier, single NGAL levels can help to
predict outcome (that is, severity of AKI, need for RRT,
and mortality) [4-6]. However, Zeng and colleagues [7]
measured urinary NGAL levels in 199 patients undergoing
surgery pre-operatively and regularly until day 14 post-
dictors for renal recovery after AKI had occurred. Defining
renal recovery in patients receiving RRT is particularly
challenging. Urine output may aid the clinician but often is
confounded by the use of diuretics, and serum creatinine is
of little value. The specific role of novel biomarkers in pre-
dicting successful discontinuation of RRT has not been
studied but would require confirmation that the biomarker
(or panel of biomarkers) is not cleared during RRT.
Schilder and colleagues measured serial NGAL levels in
serum and ultrafiltrate for 9 hours in 42 patients on RRT
with particular attention to volume balance and delivered
dose. A biocompatible cellulose triacetate hemofilter with
a cutoff of approximately 40 kDa was used, and the sieving
coefficient (SC) for NGAL was determined. The SC is the
ratio of the concentration of solutes in the ultrafiltrate to
that of the plasma. Thus, an SC of 1 describes complete
permeability whereas an SC of 0 implies complete imper-
meability. Importantly, SC not only is driven by the mo-
lecular weight/size of the solute but also is dependent on
protein binding and porosity of the filter. NGAL has a
molecular weight of 25 kDa; thus, one may expect it to be
relatively easily filtered. If that were to be the case, then
monitoring of NGAL levels during RRT would tell us littleCentral Ltd. The licensee has exclusive rights to distribute this article, in any
n. After this time, the article is available under the terms of the Creative Commons
/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
erly cited. The Creative Commons Public Domain Dedication waiver (http://
applies to the data made available in this article, unless otherwise stated.
Ostermann and Forni Critical Care Page 2 of 22014, 18:155
http://ccforum.com/content/18/3/155save an approximation to adequacy! What was observed
was no difference between NGAL levels pre- and post-
filter with a relatively low SC of between 0.2 and 0.4 and a
decrease of the observed SC with time. Certainly, there is
no evidence from this study that RRT affects plasma
NGAL levels in any significant manner. The relatively low
SC probably reflects a degree of protein binding as it is
well known to bind with other proteins such as bacterial
siderophores. Indeed, this study confirms an earlier, albeit
smaller, study on NGAL clearance which used a polysul-
phone filter and similarly observed little impact on SC
values [8]. It should be borne in mind, however, that the
SC profile differs between filters as does the homogeneity
of pore size. Interestingly, the only other study to use an
experimental hemofiltration set-up with a polysuphone fil-
ter gave calculated SC values of 0.2 to 0.4 [9]. In that
study, unlike the one by Schilder and colleagues, SC values
increased with time, and this increase was attributed to
membrane adsorption. No significant differences were ob-
served with differing anticoagulants, although the ob-
served concentrations of NGAL in the ultrafiltrate of
those treated with citrate showed a trend toward lower
concentrations which may reflect less generated NGAL
from sequestered inflammatory cells.
So how will this study change our practice? At this
juncture, in truth, probably not at all, but it does open
the door to future studies. It is clearly important, when
evaluating the role of any AKI biomarker to guide ther-
apy, including tailoring or discontinuing RRT, to confirm
that the biomarker is not removed by the treatment it-
self. In the future, identification of a particular marker
(either a single value or trends) which indicates renal re-
covery while on RRT may allow timely discontinuation
and prevent unnecessary exposure to extracorporeal cir-
cuits. Clearly, at present, we have no tools to allow us to
do this, but this study does provide some potential. As
we are aware, predicting anything in the intensive care
unit environment is difficult, especially - as Niels Bohr
famously said - if it’s about the future! Hopefully, in the
not too distant future, patients may benefit from the
predictive tools we are yet to discover.
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